On July 17, Sino Biopharmaceutical fell 3.04% in regular trading, trading at 4.98 HKD/share, with turnover of approximately 170 million HKD. The decline came amid broad-based selling pressure across the pharmaceutical sector.

The entire pharmaceuticals sector experienced significant weakness, with major peers declining in tandem: CSPC Pharmaceutical Group fell 3.95%, Hengrui Medicine fell 3.71%, Asymchem Laboratories fell 7.38%, Luye Pharma fell 4.05%, and Hansoh Pharmaceutical fell 2.96%. The synchronized pullback suggests sector-level headwinds rather than company-specific factors, particularly as Sino Biopharmaceutical had accumulated gains in recent sessions following a series of positive catalysts including its TQC3721 licensing deal with AstraZeneca worth up to $1.9 billion, deepened strategic cooperation with GSK in respiratory therapies, and the breakthrough therapy designation for TRD205 by the CDE.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)